Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Raychaudhuri, Mithu | Mukhopadhyay, Debashis; *
Affiliations: Structural Genomics Section, Saha Institute of Nuclear Physics, Kolkata, India
Correspondence: [*] Correspondence to: Debashis Mukhopadhyay, Ph.D., Structural Genomics Section, Saha Institute of Nuclear Physics, 1/AF, Bidhan Nagar, West Bengal, Kolkata 700 064, India. Tel.: +91 33 2337 5345 49; Fax: +91 33 2337 4637; E-mail: debashis.mukhopadhyay@saha.ac.in.
Abstract: The amyloid-β protein precursor (AβPP) is processed by various proteases located along the endosomal lysosomal pathway and any alteration in its trafficking would be important in the pathogenesis of Alzheimer's disease (AD). Our current study is based on the clinical evidence that an AβPP intracellular domain (AICD) “adaptor” protein, growth factor receptor protein binding protein 2 (Grb2), gets concentrated in neuronal cell bodies in AD patients. Here we show that both endogenous and exogenously transfected Grb2 interact with AβPP in Neuro 2A cells. Endogenous Grb2 partially co-localizes to late endosomal compartments along with AβPP and AICD. Increase in the concentration of Grb2 confines it in enlarged late endosomes leading to more sequestration of AβPP and AICD within these compartments. This confinement of AβPP due to Grb2 overexpression affects its turnover by inhibiting its release via exosomal vesicles. As a consequence, the level of intracellular AβPP and AICD increases. The effect of Grb2 overexpression has been verified by knocking down Grb2 as well as by overexpressing Grb2 in Grb2 knocked down cells. Having established the Grb2-mediated trafficking of AICD and its impairment, the significance of its consequence has now become apparent in the downstream events of AD pathogenesis.
Keywords: Amyloid-β protein precursor (AβPP), AβPP intracellular domain (AICD), endosomal-lysosomal pathway, exosome, Grb2
DOI: 10.3233/JAD-2010-1371
Journal: Journal of Alzheimer's Disease, vol. 20, no. 1, pp. 275-292, 2010
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl